Quotient Sciences Ltd.

Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP) FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, US. This comprises a Pneumatic Closed Transfer System, which maintains blend integrity during safe material transfer, and a Flexible Dispensing Isolator designed to improve operator safety and remove the need for specialised cleaning procedures. Quotient Sciences now has expanded capabilities for handling highly potent active pharmaceutical ingredients (HPAPI) and products with occupational exposure limits (OELs) at or below 1µg/m³. The new additions also allow seamless integration with existing equipment, facilitating the production process for complex drug molecules. The extended partnership aims to guarantee a reliable commercial supply of FOP therapy while expanding capacity to handle multiple highly potent compounds at commercial scale. This supports the need for flexible solutions in treating rare diseases where patient populations are small and product volumes are limited. Ipsen selected Quotient Sciences for its established operational capabilities and extensive experience in managing global shipments. The company will be responsible for ensuring the secure and timely delivery of the therapy to international markets. Quotient Sciences Philadelphia vice-president and general manager Marlene Leuenberger said: “This significant investment in advanced containment and manufacturing technology at our Boothwyn facility underscores Quotient Sciences’ unwavering commitment to supporting patients with ultra-rare diseases. “By expanding our capabilities in handling highly potent compounds, we are not only ensuring a reliable supply of critical therapies like Sohonos (Palovarotene) for the FOP community, but also reinforcing our promise to deliver flexible, high-quality solutions for our partners with specialised needs, especially for highly potent compounds.” In September 2025, Quotient Sciences entered a partnership with the UK’s Centre for Process Innovation (CPI) to expedite the creation of ribonucleic acid (RNA)-based treatments. The content above comes from the network. if any infringement, please contact us to modify.

Quotient Sciences, an integrated contract research, development and manufacturing organization (CRDMO) headquartered in Philadelphia, has extended its commercial manufacturing partnership with Ipsen to produce a treatment for fibrodysplasia ossificans progressiva (FOP). Under the agreement, Quotient will continue manufacturing Sohonos (palovarotene), a therapy approved by the U.S. Food and Drug Administration in 2023 for the ultra-rare disease, which affects fewer than 1,000 people worldwide, according to the company. The product is a highly potent molecule requiring specialized handling and containment. As part of the partnership, Ipsen invested in new equipment at Quotient’s Boothwyn, Pennsylvania facility, including a pneumatic closed transfer system and a flexible dispensing isolator. The company upgrades are designed to ensure safe material transfer, protect operators, and eliminate certain cleaning requirements while maintaining blend integrity. Quotient said the additions expand its capabilities for manufacturing highly potent active pharmaceutical ingredients and drug products with occupational exposure limits at or below 1 µg/m³. The equipment is integrated with existing infrastructure to support commercial-scale production and global distribution, according to the announcement. The extended agreement is intended to ensure continued commercial supply of the FOP therapy and broaden the site’s ability to handle multiple highly potent compounds at commercial scale. The announcement follows additional recent investments by Quotient in technology-enabled development. In December 2025 , the company entered a multi-year partnership with Canada-based Intrepid Labs to incorporate artificial intelligence into early-stage formulation development. Under that agreement, Quotient gained access to Intrepid’s machine learning platform to support formulation design and optimization within its Translational Pharmaceutics platform.

PHILADELPHIA , Feb. 26, 2026 /PRNewswire/ -- Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide. This collaboration reinforces Quotient Sciences' commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs. Sohonos (Palovarotene), approved by the FDA in 2023, is a highly potent molecule which requires specialized handling and containment to protect both the facility and manufacturing operators. As part of the partnership, Ipsen has invested in new equipment at Quotient Sciences' Boothwyn, PA facility, including a Pneumatic Closed Transfer System, which ensures safe material transfer without impacting blend segregation, and a Flexible Dispensing Isolator, which enhances operator safety and eliminates special cleaning requirements. Quotient Sciences brings a world-class facility, an experienced team, reliable supply capabilities, and the ability to manage global shipments, ensuring seamless delivery and operational excellence throughout the partnership. These additions expand Quotient Sciences' capabilities for handling and manufacturing highly potent API (HPAPI) drug molecules and products, with known OELs at or below 1 µg/m³, while enabling seamless integration with existing equipment. The partnership will ensure sustained commercial supply for FOP therapy and broaden capabilities to handle multiple highly potent compounds at commercial scale, addressing critical needs in rare disease treatment. Marlene Leuenberger, VP and General Manager, Quotient Sciences, Philadelphia commented: "This significant investment in advanced containment and manufacturing technology at our Boothwyn facility underscores Quotient Sciences' unwavering commitment to supporting patients with ultra-rare diseases. By expanding our capabilities in handling highly potent compounds, we are not only ensuring a reliable supply of critical therapies like Sohonos (Palovarotene) for the FOP community, but also reinforcing our promise to deliver flexible, high-quality solutions for our partners with specialized needs especially for highly potent compounds. About Quotient Sciences : Quotient Sciences is an integrated CRDMO (contract research, development and manufacturing organization) providing services across the entire drug development and clinical pathway. Our flagship platform for drug development, Translational Pharmaceutics®, has been trusted for integrated drug product formulation development and manufacturing with clinical testing activities for over 17 years. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. To learn more, visit quotientsciences.com. SOURCE Quotient Sciences 21% more press release views with Request a Demo